This clinical trial is focused on studying a group of diseases known as ANCA-associated vasculitis, which includes conditions like granulomatosis with polyangiitis and microscopic polyangiitis. These are rare diseases where the body’s immune system mistakenly attacks its own blood vessels, causing inflammation. The study aims to evaluate the effectiveness of a medication called prednisone, which is a type of steroid used to reduce inflammation, in maintaining remission, or the absence of disease symptoms, in patients who have already achieved remission with treatments like rituximab, cyclophosphamide, or methotrexate.
Participants in the study will be divided into groups to receive either a continued low dose of prednisone or a placebo, which is a substance with no active medication, to compare the effects on maintaining remission. The study will last for about 30 months, during which the participants’ health will be monitored to see if they remain free of disease symptoms. The goal is to determine if continuing prednisone helps prevent the return of symptoms better than stopping it after a short period.
Throughout the study, participants will receive regular check-ups to monitor their health and any potential side effects. The study will also track the occurrence of any disease flare-ups, which are periods when symptoms return or worsen. This research is important for understanding how to best manage ANCA-associated vasculitis and improve long-term outcomes for patients living with these conditions.
France 
